IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

ALNYLAM PHARMACEUTICALS, INC.,)	
Plaintiff,	.)	C.A. No. 22-335-CFC (CONSOLIDATED)
v.)	
MODERNA, INC., MODERNATX, INC., and MODERNA US, INC.,)	
Defendants.)	
9		

PROPOSED FINAL JUDGMENT

Pursuant to and for the reasons set forth in Plaintiff Alnylam Pharmaceuticals, Inc. ("Alnylam") and Defendants Moderna, Inc., ModernaTX, Inc., and Moderna US, Inc.'s (collectively, "Moderna") August 25, 2023 Stipulation And Joint Motion For Entry Of Final Judgment Of Non-Infringement ("Stipulation"), the Court ENTERS FINAL JUDGMENT of:

1. non-infringement of all asserted claims of U.S. Patent No. 11,246,933 ("the '933 Patent") and U.S. Patent No. 11,382,979 ("the '979 Patent") (collectively, the "Patents-in-Suit") in view of the Court's Claim Construction Order (D.I. 125).

The Court also DISMISSES WITHOUT PREJUDICE Moderna's affirmative defenses and counterclaims.

Each party is to bear its own costs and attorneys' fees incurred through the date of the Stipulation.

This is a final, appealable judgment.

IT IS SO ORDERED.

20	ORDERED	this	30/h	day	กร์	Avgust	2023
3 U	UNDERED,	min2		uay	VI		

United States District Judge

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

ALNYLAM PHARMACEUTICALS, INC.,)))
Plaintiff,) C.A. No. 22-cv-335-CFC (CONSOLIDATED)
V.	
MODERNA, INC., MODERNATX, INC., and MODERNA US, INC.,	
Defendants.)
	,

[PROPOSED] CLAIM CONSTRUCTION ORDER

The Court, having considered the parties' briefing on claim construction (D.I. 95), and in accordance with the reasoning set forth during the claim construction hearing on August 9, 2023 (D.I. 115), and the Court's subsequent August 9, 2023 Order (D.I. 114), IT IS HEREBY ORDERED that the terms of U.S. Patent Nos. 11,246,933 (the "'933 Patent") and 11,382,979 (the "'979 Patent") set forth below are construed as follows:

Claim Term	Claim Number(s)	Construction	
"cationic lipid"	All asserted claims of the '933 Patent All asserted claims of	Plain and ordinary meaning which is "a lipid that is positively charged or that may be protonated at physiological pH"	
	the '979 Patent		
"branched alkyl"	All asserted claims of the '933 Patent	"A saturated hydrocarbon moiety group in which one carbon atom	

Claim Term	Claim Number(s)	Construction
	All asserted claims of the '979 Patent	in the group (1) is bound to at least three other carbon atoms, and (2) is not a ring atom of a cyclic group."
"branched C ₁₀ -C ₂₀ alkyl"	All asserted claims of the '933 Patent	"A saturated hydrocarbon moiety group with 10 to 20 carbon atoms and in which one carbon atom in
	All asserted claims of the '979 Patent	the group (1) is bound to at least three other carbon atoms, and (2) is not a ring atom of a cyclic group"
"R ¹³ is a branched C ₁₀ -C ₂₀ alkyl"		"R ¹³ is a saturated hydrocarbon moiety group with 10 to 20 carbon atoms and in which one carbon atom in the group (1) is bound to at least three other carbon atoms and (2) is not a ring atom of a cyclic group."

Further, the parties have agreed to the following constructions, as set forth in the Joint Claim Construction Brief (D.I. 95):

Term	Agreed Construction
"directly bonded"	"Covalently bonded without any
	intervening atoms"
"primary group"	"the head group and central moiety"
"optionally comprises a primary,	"may or may not contain an amine,
secondary, or tertiary amine"	where the amine may be primary,
	secondary, or tertiary"
"where the branching occurs at the α -	"where the branching occurs at a
position relative to the	carbon atom next to the
[biodegradable/ester] group"	[biodegradable/ester] group"
"nucleic acid"	"a molecule composed of nucleotides,
	including modified nucleotides"
"an RNA"	"comprising ribonucleic acid"

The construction of the term "head group" is held in abeyance until such time as this Court conducts an additional hearing as discussed during the August 9, 2023 hearing, if necessary.

McDermott Will & Emery LLP

/s/ Ethan H. Townsend

Ethan H. Townsend (#5813)
The Nemours Building
1007 North Orange Street, 10th Floor
Wilmington, DE 19801
Tel.: (302) 888-3911
ehtownsend@mwe.com

OF COUNSEL:

William G. Gaede, III Anisa Noorassa McDermott Will & Emery LLP 415 Mission Street, Suite 5600 San Francisco, CA 94105

Sarah Chapin Columbia Sarah J. Fischer McDermott Will & Emery LLP 200 Clarendon Street, Floor 58 Boston, MA 02116-5021

Ian B. Brooks
Timothy M. Dunker
McDermott Will & Emery LLP
500 N. Capitol Street NW
Washington, DC 20003

FARNAN LLP

/s/ Michael J. Farnan

Brian E. Farnan (#4089)
Michael J. Farnan (#5165)
919 N. Market Street, 12th Floor
Wilmington, Delaware 19801
Tel.: (302) 777-0300
bfarnan@farnanlaw.com
mfarnan@farnanlaw.com

OF COUNSEL:

Elizabeth M. Flanagan (#5891) Brianna Lee Chamberlin Cooley LLP 30 South 9th Street, 7th Floor Minneapolis, MN 55402

W. Chad Shear (#5711) Geoffrey D. Biegler Cooley LLP 10265 Science Center Drive San Diego, CA 92121

Elizabeth L. Stameshkin Angela Madrigal Cooley LLP 3175 Hanover Street Palo Alto, CA 94304 Bhanu K. Sadasivan, Ph.D. McDermott Will & Emery LLP 650 Live Oak Avenue, Suite 300 Menlo Park, CA 94025-4885 Attorneys for Moderna, Inc., ModernaTX, Inc., and Moderna US, Inc.

Attorneys for Plaintiff
Alnylam Pharmaceuticals, Inc.

Dated: August 16, 2023

IT IS SO ORDERED this 21st day of Asset , 2023.

Chief Judge Colm F. Connolly

Ch 7: C